SureTrader
Home > Boards > US Listed > Biotechs > Advaxis, Inc. (ADXS)

Terry, I'm glad you brought this up.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Gantor50 Member Profile
Member Level 
Followed By 52
Posts 1,638
Boards Moderated 0
Alias Born 01/13/14
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 2/15/2018 5:29:09 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2018 5:33:13 PM
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of M... Business Wire - 2/13/2018 8:30:00 AM
Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic ... Business Wire - 2/12/2018 9:15:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/6/2018 5:02:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/29/2018 5:04:42 PM
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conferen... Business Wire - 1/29/2018 8:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 1/25/2018 5:04:55 PM
Traders News Source Issues Stocks on Watch and a New Feature Report InvestorsHub NewsWire - 1/25/2018 8:05:00 AM
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in Internation... Business Wire - 1/25/2018 8:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 1/9/2018 5:18:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 6:02:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 6:01:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 12/21/2017 6:05:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2017 4:21:23 PM
Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update Business Wire - 12/20/2017 4:15:00 PM
Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic PR Newswire (US) - 12/20/2017 8:05:00 AM
Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017 Business Wire - 12/14/2017 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/4/2017 4:35:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/4/2017 4:31:53 PM
Quotidian Technical Highlights on Selected Biotech Stocks -- Advaxis, Grifols, Juno Therapeutics, and Lexicon Pharma PR Newswire (US) - 11/27/2017 7:05:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 11/9/2017 5:25:39 PM
Gantor50 Member Level  Friday, 10/06/17 12:06:08 PM
Re: A deleted message
Post # of 55317 
Terry, I'm glad you brought this up. I have read you make this point over the years, and I glady cede to you when it comes to the history of ADXS.

Let's assume you are 100% correct about HER2. My question is even if that was true, based on your opinion, do you see enough benefits in HER2 to outweigh the risks? For example, say a Doctor told me he might be able to save my life and eliminate my particular cancer with a HER2 construct. But he also warned me that approx. 5 out of 100 people who take the drug he is going to give me will die from a heart attack, and asked me what I want to do.

In other words, do you think HER2 would be viable with a (hypothetical) black box label? A number of drugs have been very successful even after a black box label because patients determined that the potential benefits outweighed the potential risks.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist